Form 2 crystalline polymorph of a salt of N-(1-6-(ethynyl-3-oxo-hexahydro-furo(3,2-b)pyrrole-4-carbonyl)-3-methyl-butyl)-4-(5-fluoro-2-(4-methyl-piperazinyl)thiazol-4-yl)-benzamide useful as cysteine protease inhibitor

There is provided Form 2 crystalline polymorph consisting of N-[1-6-(ethynyl-3-oxo-hexahydro-furo[3,2-b]pyrrole-4-carbonyl)-3-methyl-butyl]-4-[5-fluoro-2-(4-methyl-piperazin-1-yl)thiazol-4-yl]-benzamide monohydrochloride and N-[1-6-(ethynyl-3-oxo-hexahydro-furo[3,2-b]pyrrole-4- carbonyl)-3-methyl-bu...

Full description

Saved in:
Bibliographic Details
Main Authors Carr, Andrew, Salvadore-Oden, Lourdes, Grabowska, Urszula, Diaz Perez, Victor M
Format Patent
LanguageEnglish
Published 02.02.2017
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:There is provided Form 2 crystalline polymorph consisting of N-[1-6-(ethynyl-3-oxo-hexahydro-furo[3,2-b]pyrrole-4-carbonyl)-3-methyl-butyl]-4-[5-fluoro-2-(4-methyl-piperazin-1-yl)thiazol-4-yl]-benzamide monohydrochloride and N-[1-6-(ethynyl-3-oxo-hexahydro-furo[3,2-b]pyrrole-4- carbonyl)-3-methyl-butyl]-4-[5-fluoro-2-(4-methyl-piperazin-1-yl)thiazol-4-yl]-benzamide hydrate monohydrochloride, its use as a medicament and methods for its preparation.
Bibliography:Application Number: AU20140307850